Placental Pathology and Inflammatory Factor Analysis of OAPS

Antiphospholipid Syndrome in Pregnancy Clinical Trial

Official title:

Placental Pathology and Inflammatory Factor Analysis of Obstetric Antiphospholipid Syndrome Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05378516
• Other study ID #: yjjbear2022
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2022
• Source: Peking University People's Hospital
• Contact: Jingjing Yang, deputy chief physician, doctor
• Phone: 0086-13810625484
• Email: yjjbear2013[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.

Description:

1. To clarify the correlation between antiphospholipid antibody, ACC1 expression level, Treg cell and placental pathological changes associated with antiphospholipid syndrome. 2. Reveal that antiphospholipid antibodies affect Treg cell differentiation through the key enzyme of lipid metabolism ACC1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2023
• Est. primary completion date: May 12, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. pregnant women with antiphospholipid syndrome (diagnosed by experts with clinical evidence) and healthy pregnant women without antiphospholipid syndrome as a control group

2. consent to join this study and finish the informed consents Exclusion Criteria: pregnant women with other autoimmune diseases

Related Conditions & MeSH terms

• Antiphospholipid Syndrome
• Antiphospholipid Syndrome in Pregnancy
• Syndrome

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	PekingUPH	Pekin

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	expression of ACC1 in placenta in pregnancy with/without antiphospholipid syndrome		in two years